Latest Financial Results News

Merchant House International Limited reports the completion of its Tianjin asset sale and the cessation of AMI operations, signaling a strategic wind-up and delisting plan.

Advanced Braking Technology Ltd (ASX: ABV) reported a robust 24% increase in product sales revenue for Q2 FY25, driven by international expansion and the launch of its innovative BrakeiQ system. The company’s underlying profit also grew by 25%, underscoring operational efficiencies and a strong global pipeline.

Southern Cross Gold Ltd has officially become a wholly owned subsidiary of Southern Cross Gold Consolidated Ltd following a scheme of arrangement, with shareholders receiving new securities and the company set for ASX delisting.

Spacetalk Ltd reports robust growth in paid mobile subscribers and annual recurring revenue for Q2 FY25, underpinned by strategic international expansion and disciplined cost management.

AMCIL Limited posted a half-year profit of $3.6 million, down 12.6%, yet its portfolio outperformed the S&P/ASX 200 with an 8.7% return. The company declared a steady interim dividend amid cautious market conditions.

Galilee Energy reports a $1.9 million R&D tax refund and terminates its merger with Vintage Energy, while maintaining steady progress at its Glenaras Gas Project and a robust cash position of $4.38 million.

Amcor plc and Berry Global Group, Inc. have entered into a definitive all-stock merger agreement, positioning the combined entity as a global leader in consumer and healthcare packaging with expected annual synergies of $650 million.

IGO Limited has ceased all work on Lithium Hydroxide Plant 2 at its Kwinana Refinery, anticipating a substantial impairment loss in its upcoming half-year financial results.

BSA Limited reported a robust Q2 FY2025 with revenue up 10.7% and EBITDA surging 31.5%, underpinned by a key contract extension with nbn. The company has upgraded its full-year EBITDA guidance, signaling confidence in sustained profitability.

KMD Brands reports improving sales in direct-to-consumer channels for FY25’s first five months, offset by ongoing wholesale challenges and a forecasted dip in EBITDA.

Nyrada Inc. reports promising preclinical results for its lead drug NYR-BI03, showing an 86% cardioprotective effect, alongside a strong financial position bolstered by a AU$3.29 million capital raise. The company has submitted its Phase Ia clinical trial package, setting the stage for human testing.

Vonex Limited reports solid operational improvements and customer satisfaction in Q2 FY25, while endorsing Maxo Telecommunications’ takeover offer and planning a $13 million capital raise to manage debt.